antibody

Rabbit anti VEGFR-2 Polyclonal antibody

MBS462167

0.1 mg

250 USD

polyclonal

rabbit

nonconjugated

human, mouse, dog

western blot, ELISA, immunohistochemistry

Antibody

Rabbit anti VEGFR-2 Polyclonal antibody

VEGFR-2 (CD309)

Rabbit anti-VEGFR-2; Vascular endothelial growth factor receptor 2 (VEGFR-2); KDR/ Flk-1; CD309 antigen

vascular endothelial growth factor receptor 2; Vascular endothelial growth factor receptor 2; vascular endothelial growth factor receptor 2; soluble VEGFR2; OTTHUMP00000158928; fetal liver kinase 1; fetal liver kinase-1; protein-tyrosine kinase receptor Flk-1; tyrosine kinase growth factor receptor; kinase insert domain receptor (a type III receptor tyrosine kinase); Fetal liver kinase 1; FLK-1; Kinase insert domain receptor; Protein-tyrosine kinase receptor flk-1

VEGFR-2 (CD309)

KDR; KDR; FLK1; CD309; VEGFR; VEGFR2; FLK1

VGFR2_HUMAN

Polyclonal

Rabbit

Human, Mouse, Canine

This antibody recognizes ~200 and ~240 kDa of human VEGFR-2 protein. This antibody also reacts with mouse. The other species are not tested.

The Rabbit IgG is purified by Epitope Affinity Purification.

This affinity purified antibody is supplied in sterile Phosphatebuffered saline (pH7.2) containing antibody stabilizer.

Size: 100 ug/200 ul

The antibodies are stable for 12 months from date of receipt when stored at -20 degree C to -70 degree C. The antibodies can be stored at 2 degree C-8 degree C for three month without detectable loss of activity. Avoid repeated freezing-thawing cycles.

ELISA, Western Blot, Immunohistochemistry

Western Blot: 0.1-1 ug/ml. ELISA: 0.01-0.1 ug/ml. Immunoprecipitation: 2-5 ug/ml. Immunohistochemistry: 2-5 ug/m

Antigen Preparation: A synthetic peptide corresponding to the extracellular domain of human VEGFR-2 protein. This sequence is identical within human, mouse and dog.

Positive Control: HUVEC. Cellular Location: Cytoplasmic

Vascular endothelial growth factor receptor-2 (VEGFR-2), also known as CD309 antigen, the earliest known marker for vascular endothelia cells, is essential in vasculogenesis and angiogenesis. Binding of the dimeric VEGF-A to the extracellular domains of two monomeric receptors induces dimerization and activation of tyrosine kinase at tyrosine residues Y951, Y1054 and Y1059 in the kinase domain serve as positive regulatory sites. Phosphorylation at Y951 of the kinase insert is related to the migration of endothelial cells for tumor vascularization and growth.

Taro Matsumoto, et al. VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. The EMBO Journal (2005) 24, 2342-2353.

11321597

NP_002244.1

NM_002253.2

P35968

~200kDa and ~240kDa

Angiogenesis Pathway 198772!!Cytokine-cytokine Receptor Interaction Pathway 83051!!Cytokine-cytokine Receptor Interaction Pathway 460!!Endocytosis Pathway 102279!!Endocytosis Pathway 102181!!Focal Adhesion Pathway 198795!!Focal Adhesion Pathway 83067!!Focal Adhesion Pathway 478!!HIF-2-alpha Transcription Factor Network Pathway 137956!!Id Signaling Pathway 198871

Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. This gene encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc. Mutations of this gene are implicated in infantile capillary hemangiomas. [provided by RefSeq]

Function: Receptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions. Ref.6 Ref.12 Ref.15. Catalytic activity: ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate. Subunit structure: Interacts with MYOF. By similarity. Interacts with SHB; upon VEGF activation. Interacts with HIV-1 Tat. Ref.7 Ref.8. Subcellular location: Membrane; Single-pass type I membrane protein. Post-translational modification: Phosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214. Ref.9 Ref.10 Ref.11 Ref.12. Involvement in disease: Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [. MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma. Ref.16 Ref.19. Sequence similarities: Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.Contains 7 Ig-like C2-type (immunoglobulin-like) domains.Contains 1 protein kinase domain.

0.1 mg

250 USD